The CBIA Bioscience Growth Council has written to Governor Ned Lamont of Connecticut opposing HB 6447. Their letter states:
“The Connecticut biopharmaceutical community opposes HB 6447, … which would institute price controls on drugs, requiring drug manufacturers to pay an 80% penalty on price increases greater than the consumer price index plus 2%. The bill does not address medicine affordability in a practical and effective way and would undermine biomedical research and development innovation. We believe the legislation, though well-intentioned, is flawed on at least five fronts.”